Provided by Tiger Fintech (Singapore) Pte. Ltd.

ADC Therapeutics SA

3.12
-0.0587-1.85%
Volume:154.98K
Turnover:492.21K
Market Cap:351.14M
PE:-1.98
High:3.22
Open:3.18
Low:3.12
Close:3.18
52wk High:3.97
52wk Low:1.05
Shares:112.50M
Float Shares:92.24M
Volume Ratio:0.22
T/O Rate:0.17%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5758
EPS(LYR):-1.6246
ROE:-705.53%
ROA:-22.99%
PB:-1.76
PE(LYR):-1.92

Loading ...

ADC Therapeutics SA Reports Increased Net Loss of $56.6 Million in Q2 2025, EPS Down to $0.50; Product Revenues Rise to $18.1 Million

Reuters
·
Aug 12

BRIEF-ADC Therapeutics Q2 Income From Operations USD -44.147 Million Vs. IBES Estimate USD -44.5 Million

Reuters
·
Aug 12

ADC Therapeutics - Q2 Adj Loss per Share $0.25

THOMSON REUTERS
·
Aug 12

ADC Therapeutics Q2 Revenue USD 18.839 Million VS. Ibes Estimate USD 17.9 Million

THOMSON REUTERS
·
Aug 12

ADC Therapeutics Q2 Net Income USD -56.646 Million VS. Ibes Estimate USD -53.3 Million

THOMSON REUTERS
·
Aug 12

ADC Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update

THOMSON REUTERS
·
Aug 12

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Aug 11

ADC Therapeutics SA to Release Second Quarter 2025 Financial Results

Reuters
·
Aug 06

ADC Therapeutics SA Announces New Inducement Plan with Stock Option Grants to Attract Top Talent

Reuters
·
Aug 02

ADC Therapeutics SA expected to post a loss of 47 cents a share - Earnings Preview

Reuters
·
Aug 01

ADC Therapeutics Announces New Inducement Plan Granting Stock Options to New Employee

Reuters
·
Jul 02

ADC Therapeutics files to sell 27.73M common shares for holders

TIPRANKS
·
Jul 01

ADC Therapeutics Is Maintained at Outperform by RBC Capital

Dow Jones
·
Jun 20

RBC Adjusts Price Target on ADC Therapeutics Ltd to $5 From $8, Maintains Outperform, Speculative Risk Rating

MT Newswires Live
·
Jun 20

RBC Capital Sticks to Its Buy Rating for ADC Therapeutics (ADCT)

TIPRANKS
·
Jun 20

ADC Therapeutics falls -4.6%

TIPRANKS
·
Jun 18

ADC Therapeutics announces new data from Phase 2 trial of Zynlonta

TIPRANKS
·
Jun 16

ADC Therapeutics SA to Present Updated ZYNLONTA® Trial Data at International Conference on Malignant Lymphoma

Reuters
·
Jun 16

ADC Therapeutics Is Maintained at Buy by Guggenheim

Dow Jones
·
Jun 13

ADC Therapeutics to Cut 30% of Workforce, Shutter UK Site

MT Newswires Live
·
Jun 12